• Daiichi Sankyo’s Datroway won European Commission clearance for first-line unresectable or metastatic TNBC patients ineligible for PD-1/PD-L1 inhibitors.
• Decision relied on Phase 3 TROPION-Breast02 data showing median overall survival of 23.7 months vs 18.7 months with chemotherapy.
• Datroway is co-developed with AstraZeneca; it is now cleared in the EU for two breast cancer indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607310230BIZWIRE_USPR_____20260730_BW636069) on July 31, 2026, and is solely responsible for the information contained therein.